[HTML][HTML] Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
Abstract Coronavirus disease 2019 (COVID-19) represents an unmet clinical need, due to a
high mortality rate, rapid mutation rate in the virus, increased chances of reinfection, lack of …
high mortality rate, rapid mutation rate in the virus, increased chances of reinfection, lack of …
Femoral head avascular necrosis in COVID-19 survivors: a systematic review
AAA Hassan, AA Khalifa - Rheumatology International, 2023 - Springer
The current systematic review aimed to document published cases of femoral head
avascular necrosis (FHAVN) post-COVID-19, to report the COVID-19 disease characteristics …
avascular necrosis (FHAVN) post-COVID-19, to report the COVID-19 disease characteristics …
A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic …
HM Marzouk, MR Rezk, AS Gouda… - Microchemical …, 2022 - Elsevier
Modern pharmaceutical analysis is paying a lot of attention to the stability of novel drug
formulations as well as establishment of suitable stability-indicating approaches. In the …
formulations as well as establishment of suitable stability-indicating approaches. In the …
Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs “Remdesivir and Favipiravir”: Green assessment with application …
DAM Noureldeen, JM Boushra, AS Lashien… - Microchemical …, 2022 - Elsevier
A great demand for discovering new therapeutic solutions has been considered all over the
world for managing the rapidly progressing COVID-19 pandemic. Remdesivir (REM) and …
world for managing the rapidly progressing COVID-19 pandemic. Remdesivir (REM) and …
Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
M AlQahtani, N Kumar, D Aljawder, A Abdulrahman… - Scientific Reports, 2022 - nature.com
Favipiravir has antiviral activity against influenza, West Nile virus, and yellow fever virus and
against flaviviruses. The objective of this pilot study was to compare three arms: favipiravir; …
against flaviviruses. The objective of this pilot study was to compare three arms: favipiravir; …
Rapid and ecofriendly UPLC quantification of Remdesivir, Favipiravir and Dexamethasone for accurate therapeutic drug monitoring in Covid-19 Patient's plasma
AA Emam, EA Abdelaleem, EH Abdelmomen… - Microchemical …, 2022 - Elsevier
Innovative therapeutic protocols to the rapidly spreading coronavirus disease (COVID19)
epidemic is highly required all across the world. As demonstrated by clinical studies …
epidemic is highly required all across the world. As demonstrated by clinical studies …
Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2
MS Bekheit, SS Panda, AS Girgis - European Journal of Medicinal …, 2023 - Elsevier
The SARS-CoV-2 pandemic is considered as one of the most disastrous pandemics for
human health and the world economy. RNA-dependent RNA polymerase (RdRp) is one of …
human health and the world economy. RNA-dependent RNA polymerase (RdRp) is one of …
[HTML][HTML] An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: promises and challenges
X Xu, Y Chen, X Lu, W Zhang, W Fang, L Yuan… - Biochemical …, 2022 - Elsevier
The highly transmissible variants of SARS-CoV-2, the causative pathogen of the COVID-19
pandemic, bring new waves of infection worldwide. Identification of effective therapeutic …
pandemic, bring new waves of infection worldwide. Identification of effective therapeutic …
[HTML][HTML] From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era
G Miao, Z Chen, H Cao, W Wu, X Chu, H Liu… - Biomedicine & …, 2023 - Elsevier
The COVID-19 pandemic has affected millions of people and posed an unprecedented
burden on healthcare systems and economies worldwide since the outbreak of the COVID …
burden on healthcare systems and economies worldwide since the outbreak of the COVID …
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study
R Sirijatuphat, W Manosuthi… - Emerging Microbes & …, 2022 - Taylor & Francis
We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia
and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia …
and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia …